📊 IRWD Key Takeaways
Is Ironwood Pharmaceuticals Inc. (IRWD) a Good Investment?
Ironwood demonstrates strong operational profitability with a 33.3% operating margin and robust free cash flow generation of $127M, supported by a solid interest coverage ratio of 13.6x. However, the company faces significant balance sheet challenges with negative stockholders' equity of -$261.8M and declining revenue (-15.7% YoY), creating uncertainty about long-term financial sustainability despite near-term cash generation capability.
Ironwood Pharmaceuticals shows solid underlying profitability and unusually strong cash conversion, with high operating margins, positive net income, and free cash flow materially above reported earnings. However, the 15.7% revenue decline, negative stockholders' equity, and only modest liquidity weaken the quality of the fundamental profile and argue for a neutral stance until top-line stability improves.
Why Buy Ironwood Pharmaceuticals Inc. Stock? IRWD Key Strengths
- Exceptional free cash flow generation at 42.9% FCF margin, providing financial flexibility
- Strong operating margins at 33.3% demonstrating operational efficiency in core business
- Healthy interest coverage ratio of 13.6x indicating current debt servicing capacity
- Substantial cash position of $215.5M relative to near-term obligations
- Strong profitability with a 33.3% operating margin and positive net income
- Excellent cash generation, with $127.01M of free cash flow and a 42.9% FCF margin
- Manageable debt servicing capacity, supported by 13.6x interest coverage and cash exceeding long-term debt
IRWD Stock Risks: Ironwood Pharmaceuticals Inc. Investment Risks
- Critical balance sheet deterioration with negative stockholders' equity of -$261.8M indicating potential insolvency or past accumulated losses
- Revenue contraction of -15.7% YoY suggesting declining product demand or market share loss in competitive pharma sector
- High leverage with $199.5M long-term debt against negative equity, limiting financial flexibility and refinancing options
- Minimal capital reinvestment ($34K capex) relative to $296M revenue raises concerns about product pipeline maintenance and future competitiveness
- Revenue declined 15.7% year over year, raising concern about durability of the earnings base
- Negative stockholders' equity indicates a weak balance sheet structure and makes some leverage metrics less meaningful
- Current and quick ratios of 1.13x suggest liquidity is adequate but not especially strong if operating conditions worsen
Key Metrics to Watch
- Revenue trend reversal and growth trajectory in subsequent quarters
- Net income sustainability and margin stability amid declining top-line
- Free cash flow maintenance and debt reduction progress
- Stockholders' equity recovery and path to positive book value
- Operating cash flow trends and working capital management
- Revenue growth trend and ability to return to year-over-year top-line expansion
- Sustainability of free cash flow and progress toward improving balance sheet equity
Ironwood Pharmaceuticals Inc. (IRWD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 42.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
IRWD Profit Margin, ROE & Profitability Analysis
IRWD vs Healthcare Sector: How Ironwood Pharmaceuticals Inc. Compares
How Ironwood Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ironwood Pharmaceuticals Inc. Stock Overvalued? IRWD Valuation Analysis 2026
Based on fundamental analysis, Ironwood Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ironwood Pharmaceuticals Inc. Balance Sheet: IRWD Debt, Cash & Liquidity
IRWD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ironwood Pharmaceuticals Inc.'s revenue has declined by 18% over the 5-year period, indicating business contraction. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
IRWD Revenue Growth, EPS Growth & YoY Performance
IRWD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $91.6M | -$1.4M | $-0.01 |
| Q2 2025 | $85.2M | -$860.0K | $-0.01 |
| Q1 2025 | $41.1M | -$4.2M | $-0.03 |
| Q3 2024 | $91.6M | -$1.4M | $-0.01 |
| Q2 2024 | $94.4M | -$860.0K | $-0.01 |
| Q1 2024 | $74.9M | -$4.2M | $-0.03 |
| Q3 2023 | $108.6M | $15.3M | $0.09 |
| Q2 2023 | $97.2M | $37.1M | $0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ironwood Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
IRWD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ironwood Pharmaceuticals Inc. (CIK: 0001446847)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRWD
What is the AI rating for IRWD?
Ironwood Pharmaceuticals Inc. (IRWD) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRWD's key strengths?
Claude: Exceptional free cash flow generation at 42.9% FCF margin, providing financial flexibility. Strong operating margins at 33.3% demonstrating operational efficiency in core business. ChatGPT: Strong profitability with a 33.3% operating margin and positive net income. Excellent cash generation, with $127.01M of free cash flow and a 42.9% FCF margin.
What are the risks of investing in IRWD?
Claude: Critical balance sheet deterioration with negative stockholders' equity of -$261.8M indicating potential insolvency or past accumulated losses. Revenue contraction of -15.7% YoY suggesting declining product demand or market share loss in competitive pharma sector. ChatGPT: Revenue declined 15.7% year over year, raising concern about durability of the earnings base. Negative stockholders' equity indicates a weak balance sheet structure and makes some leverage metrics less meaningful.
What is IRWD's revenue and growth?
Ironwood Pharmaceuticals Inc. reported revenue of $296.2M.
Does IRWD pay dividends?
Ironwood Pharmaceuticals Inc. does not currently pay dividends.
Where can I find IRWD SEC filings?
Official SEC filings for Ironwood Pharmaceuticals Inc. (CIK: 0001446847) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRWD's EPS?
Ironwood Pharmaceuticals Inc. has a diluted EPS of $0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRWD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ironwood Pharmaceuticals Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRWD stock overvalued or undervalued?
Valuation metrics for IRWD: ROE of N/A (sector avg: 15%), net margin of 8.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRWD stock in 2026?
Our dual AI analysis gives Ironwood Pharmaceuticals Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRWD's free cash flow?
Ironwood Pharmaceuticals Inc.'s operating cash flow is $127.0M, with capital expenditures of $34.0K. FCF margin is 42.9%.
How does IRWD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.13 (avg: 2).